Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

Díaz González, ÁlvaroHernández Guerra, ManuelPérez Medrano, IndhiraSapena, VíctorRiveiro-Barciela, MarBarreira Díaz, AnaGómez, ElenaMorillas, Rosa M.Barrio, María delEscudé, LaiaMateos, BeatrizHorta, DianaGómez, JudithConde, IsabelFerre Aracil, CarlosEl Hajra, IsmaelArencibía, AnaZamora, JavierFernández, AinhoaSalcedo, MagdalenaMolina, EstherSoria, AnnaEstévez, PamelaLópez, CarmenÁlvarez Navascúes, Carmen2023-11-172023-04-011527-3350https://hdl.handle.net/2445/203780In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.39 p.application/pdfeng(c) American Association for the Study of Liver Diseases, 2023HepatitisMalalties autoimmunitàriesHepatitisAutoimmune diseasesBudesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administrationinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess36626622